Related Experiment Video
Updated: Mar 8, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
A guide to the anti-innovation "pharmaphobia" narrative for the aspiring innovator
1Brigham & Women's Hospital, Harvard Medical School, American Enterprise Institute, Boston, MA.
Abstract:
Thomas P. Stossel is an American Cancer Society Professor of Medicine Emeritus at Harvard Medical School, Honorary Physician in the Hematology Division of Brigham & Women's Hospital, founding scientist of BioAegis Therapeutics, Visiting Scholar of The American Enterprise Institute and cofounder of Options for Children in Zambia.
Related Concept Videos
Drug Discovery: Overview
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Preclinical Development: Overview
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

